https://www.live-feeds.com/feed/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfolioContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfoliohttps://www.live-feeds.com/feed/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfolio#u14932Fri, 26 Jun 2026 23:31:35 +0000AbbVie has reached a deal to acquire Apogee Therapeutics in a transaction valued at $10.9 billion. The acquisition aims to expand AbbVie's immunology portfolio with long-acting drug candidates for inflammatory and immunological conditions. The deal includes prospects for treating eczema.What's confirmed:AbbVie is acquiring Apogee Therapeutics for $10.9 billion.The acquisition focuses on long-acting immunology and inflammatory drug candidates.The deal includes assets intended for patients with respiratory, dermatologic, and other related inflammatory conditions.The acquisition includes a p